Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
The multiple drug resistant cell line H69AR was established from NCI-H69 cells (ATCC HTB-119) that were grown in the presence of increasing concentrations of adriamycin (doxorubicin) over a total of 14 months.
The H69AR cell line is approximately 50-fold resistant to adriamycin as compared to the parental NCI-H69 cell line.
The monoclonal antibodies QCRL-1 (ATCC HB-11765) and QCRL-3 (ATCC HB-11766) will react with fixed H69AR cells.
The cell line is cross-resistant to anthracycline analogues including daunomycin, epirubicin, menogaril, and mitoxantrone as well as to acivicin, etoposide, gramicidin D, colchicine, and the Vinca alkaloids, vincristine and vinblastine.
The cells display little or no cross-resistance to bleomycin, 5-fluorouracil, and carboplatin. They have a slight collateral sensitivity to 1-dehydrotestosterone and lidocaine.
The antibodies reacts with MRP (multidrug resistance protein), a 190,000 integral membrane phosphoglycoprotein that is overexpressed in some drug-selected resistant cell lines
Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Deeley RG, Cole SP. Antibodies to a multidrug resistance protein. US Patent 6,063,621 dated May 16 2000
Hipfner DR, et al. Detection of the M(r) 190,000 multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res. 54: 5788-5792, 1994. PubMed: 7954400
Mirski SE, et al. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res. 47: 2594-2598, 1987. PubMed: 2436751
